PMID- 17726611
OWN - NLM
STAT- MEDLINE
DCOM- 20080131
LR  - 20151119
IS  - 0340-3696 (Print)
IS  - 0340-3696 (Linking)
VI  - 299
IP  - 9
DP  - 2007 Nov
TI  - Effect of etanercept on insulin secretion and insulin sensitivity in a randomized 
      trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
PG  - 461-5
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors have been used in the 
      treatment of psoriasis, which is associated with the insulin resistance syndrome. 
      The purpose of this study was to determine the effect of etanercept, a TNF-alpha 
      inhibitor, on insulin secretion and insulin sensitivity in psoriatic patients 
      with high risk factors to develop type 2 diabetes mellitus. Randomized double 
      blind clinical trial with 2 weeks of follow-up. The allocation was done by simple 
      randomization. The investigation was performed in 12 psoriatic patients with 
      indication of systemic treatment and 2 or more risk factors for type 2 diabetes 
      mellitus. Patients with infections, topical corticosteroids or salicylic acid 
      ointments for 6 weeks before the study, diabetes, acromegaly, cancer and other 
      systemic diseases were excluded. All subjects gave written informed consent to 
      participate in the study and the protocol was approved by the hospital-based 
      Ethical Committee. Etanercept was injected in a subcutaneous dose of 25 mg in 1 
      ml twice by week for 2 weeks or 1 ml of saline solution as placebo. Insulin 
      secretion was estimated with the formula for the homeostasis model analysis 
      beta-cell function index and insulin sensitivity was assessed using the 
      euglycemic-hyperinsulinemic clamp technique. There was no significant difference 
      in insulin secretion and insulin sensitivity with etanercept. Fasting serum 
      insulin levels were decreased in the etanercept group (146 +/- 117-111 +/- 87 
      pmol/l, P = 0.04). Etanercept did not modify insulin secretion and insulin 
      sensitivity in psoriatic patients with risk factors for type 2 diabetes mellitus.
FAU - Martinez-Abundis, Esperanza
AU  - Martinez-Abundis E
AD  - Medical Research Unit in Clinical Epidemiology, West National Medical Center, 
      Mexican Institute of Social Security, Guadalajara, Mexico. uiec@prodigy.net.mx
FAU - Reynoso-von Drateln, Claudia
AU  - Reynoso-von Drateln C
FAU - Hernandez-Salazar, Eduardo
AU  - Hernandez-Salazar E
FAU - Gonzalez-Ortiz, Manuel
AU  - Gonzalez-Ortiz M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20070828
PL  - Germany
TA  - Arch Dermatol Res
JT  - Archives of dermatological research
JID - 8000462
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Insulin)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Dermatologic Agents/administration & dosage/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/*etiology/physiopathology
MH  - Double-Blind Method
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Insulin/*blood
MH  - *Insulin Resistance
MH  - Male
MH  - Pilot Projects
MH  - Psoriasis/blood/*drug therapy/physiopathology
MH  - Receptors, Tumor Necrosis Factor/administration & dosage/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2007/08/30 09:00
MHDA- 2008/02/01 09:00
CRDT- 2007/08/30 09:00
PHST- 2007/08/06 00:00 [received]
PHST- 2007/08/09 00:00 [accepted]
PHST- 2007/08/30 09:00 [pubmed]
PHST- 2008/02/01 09:00 [medline]
PHST- 2007/08/30 09:00 [entrez]
AID - 10.1007/s00403-007-0784-3 [doi]
PST - ppublish
SO  - Arch Dermatol Res. 2007 Nov;299(9):461-5. doi: 10.1007/s00403-007-0784-3. Epub 
      2007 Aug 28.